Dermata Therapeutics (DRMA) Cash from Financing Activities (2020 - 2026)
Dermata Therapeutics (DRMA) posted quarterly Cash from Financing Activities of $1.9 million for Q1 2026, down 77.59% year-over-year from $8.5 million in Q1 2025, and down 54.55% quarter-over-quarter from $4.2 million in Q4 2025.
Dermata Therapeutics (DRMA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Dermata Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $1.9 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 77.59% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $5.5 million (down 64.04% YoY), while the FY2025 annual figure was $12.1 million, up 75.97% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $1.9 million, down from $4.2 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $8.5 million in Q1 2025, with the low at -$547857.0 in Q2 2025.
- The 5-year median for Cash from Financing Activities is $1.9 million (2023), against an average of $2.3 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities tumbled 17809.5% in 2023, then soared 13131.36% in 2024.
- Dermata Therapeutics' Cash from Financing Activities stood at $200.0 in 2022, then surged by 976878.5% to $2.0 million in 2023, then slumped by 103.51% to -$68568.0 in 2024, then surged by 6206.42% to $4.2 million in 2025, then slumped by 54.55% to $1.9 million in 2026.
- Business Quant data shows DRMA's Cash from Financing Activities at $1.9 million in Q1 2026, $4.2 million in Q4 2025, and -$12988.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Dermata Therapeutics | 5.40 Mn | 5.40 Mn | - | 1.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.90 Mn |
| Mar 31, 2026 | 1.90 Mn |
| Dec 31, 2025 | 4.19 Mn |
| Dec 31, 2025 | 4.19 Mn |
| Sep 30, 2025 | -12,988.00 |
| Sep 30, 2025 | -12,988.00 |
| Jun 30, 2025 | -547,857.00 |
| Jun 30, 2025 | -547,857.00 |
| Mar 31, 2025 | 8.49 Mn |
| Mar 31, 2025 | 8.49 Mn |
| Dec 31, 2024 | -68,568.00 |
| Dec 31, 2024 | -68,568.00 |
| Sep 30, 2024 | 4.62 Mn |
| Sep 30, 2024 | 4.62 Mn |
| Jun 30, 2024 | 2.34 Mn |
| Jun 30, 2024 | 2.34 Mn |
| Dec 31, 2023 | 1.95 Mn |
| Dec 31, 2023 | 1.95 Mn |
| Sep 30, 2023 | -35,419.00 |
| Sep 30, 2023 | -35,419.00 |